205 related articles for article (PubMed ID: 32430981)
21. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality.
Kang T; Huang Y; Zhu Q; Cheng H; Pei Y; Feng J; Xu M; Jiang G; Song Q; Jiang T; Chen H; Gao X; Chen J
Biomaterials; 2018 May; 164():80-97. PubMed ID: 29499438
[TBL] [Abstract][Full Text] [Related]
22. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
23. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
24. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
[TBL] [Abstract][Full Text] [Related]
25. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
26. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
27. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound-Mediated Remotely Controlled Nanovaccine Delivery for Tumor Vaccination and Individualized Cancer Immunotherapy.
Meng Z; Zhang Y; She J; Zhou X; Xu J; Han X; Wang C; Zhu M; Liu Z
Nano Lett; 2021 Feb; 21(3):1228-1237. PubMed ID: 33522825
[TBL] [Abstract][Full Text] [Related]
29. Nanobiomaterial-based vaccination immunotherapy of cancer.
Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
[TBL] [Abstract][Full Text] [Related]
30. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
31. Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy.
G Lahori D; Varamini P
Future Oncol; 2021 Feb; 17(6):711-722. PubMed ID: 33136464
[TBL] [Abstract][Full Text] [Related]
32. A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy.
Lu Z; Zhang Y; Wang Y; Tan GH; Huang FY; Cao R; He N; Zhang L
J Control Release; 2021 Apr; 332():245-259. PubMed ID: 33647430
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell-based nanovaccines for cancer immunotherapy.
Paulis LE; Mandal S; Kreutz M; Figdor CG
Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
[TBL] [Abstract][Full Text] [Related]
34. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
[No Abstract] [Full Text] [Related]
35. Dendritic Cell-Based In Situ Nanovaccine for Reprogramming Lipid Metabolism to Boost Tumor Immunotherapy.
Qin YT; Liu XH; An JX; Liang JL; Li CX; Jin XK; Ji P; Zhang XZ
ACS Nano; 2023 Dec; 17(24):24947-24960. PubMed ID: 38055727
[TBL] [Abstract][Full Text] [Related]
36. In Situ Antigen-Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy.
Li X; Zhang Y; Wu X; Chen J; Yang M; Ma F; Shi L
Small; 2022 Aug; 18(32):e2203100. PubMed ID: 35843873
[TBL] [Abstract][Full Text] [Related]
37. A Versatile Nanovaccine Enhancement Strategy Based on Suction-Inspired Physical Therapy.
Wu J; Feng Y; Guo X; Meng M; Li H; Fang H; Li Z; Lin L; Guo Z; Chen J; Tian H; Chen X
ACS Nano; 2024 Feb; 18(6):4957-4971. PubMed ID: 38288709
[TBL] [Abstract][Full Text] [Related]
38. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy.
Luo M; Liu Z; Zhang X; Han C; Samandi LZ; Dong C; Sumer BD; Lea J; Fu YX; Gao J
J Control Release; 2019 Apr; 300():154-160. PubMed ID: 30844475
[TBL] [Abstract][Full Text] [Related]
39. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
40. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
